News & Events

Xellia Pharmaceuticals Appoints Matthew Anderson as Chief Financial Officer

Xellia Pharmaceuticals Appoints Matthew Anderson as Chief Financial Officer

Copenhagen, Denmark, 13th June 2018 - Xellia Pharmaceuticals (‘Xellia’ or the ‘Company’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, announced today that it has further strengthened its leadership team by appointing Matthew Anderson as Chief Financial Officer (CFO) with immediate effect. He will be taking over from the current interim CFO, Otto Rasmussen.

Matthew brings over 20 years of corporate accounting and finance experience in international life science companies of various stages.

On welcoming him, Carl-Åke Carlsson, Xellia’s CEO said: “Matthew joins the Xellia leadership team at an exciting time as we are preparing to launch our pipeline of value-added anti-infective drug products into the US institutional market. We are also considerably expanding our North American commercial organization with a new office planned in Chicago to accompany our increased manufacturing capabilities in Cleveland, Ohio. We look forward to working with Matthew.”

Commenting on his appointment as Xellia’s new CFO, Matthew Anderson said: “I am joining a dynamic leadership team at Xellia at a pivotal stage in the Company’s development. As well as getting on with the day-to-day financial operations, I look forward to working as part of the team to support the launch of new products and the expanded business operations in the US.”

Before Xellia, Matthew served as Chief Financial Officer, Vice President and Treasurer at PharMEDium Healthcare where he was responsible for all aspects of corporate accounting and finance. Prior to joining PharMEDium, He has held various positions of increasing leadership responsibility within the Medical Products and Services business of Cardinal Health, Inc. He holds an MBA from Northwestern University Kellogg School of Management, a Master’s degree in Accountancy from DePaul University and Bachelor’s degree in Economics from Western Illinois University.  He is also a Certified Public Accountant and Chartered Global Management Accountant.

Xellia is developing a pipeline of value-added anti-infective drugs that are centred on formulation improvements for marketed drugs from its core portfolio and is intended to enhance patient care. The most advanced product in Xellia’s pipeline is its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag. This product was recently granted Qualified Infectious Disease Product (QIDP) designation from the U.S. Food & Drug Administration (FDA). QIDP provides incentives for the development of antibiotics, including priority review and eligibility for fast-track designation.


About Xellia

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs around 1,500 people.

Xellia has a portfolio of specialty anti-infectives, and is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Many of these are last resort antibiotics, often used when all other treatments have failed. Xellia is also dedicated to providing new anti-infective treatment options by improving the efficacy and delivery, and reducing toxic side effects of existing products. The Company also has early stage R&D programs focused on the discovery and formulation of new chemical entities effective against resistant microbes, with novel modes of action.

Since July 2013, Xellia has been wholly owned by Novo Holdings A/S, the holding company of the Novo Group.

Further information about Xellia can be found at:


Issued for and on behalf of Xellia by Instinctif Partners.
For more information please contact:

back to news


Melanie Toyne-SewellManaging Partner

Dr Eileen PaulAssociate Partner